Adaptive Biotechnologies Corporation ADPT R2K
Company Overview
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
Why Investors Should Care
Net profit has compounded at 23.4% per year over the last five years.
Revenue has grown at a 14.3% CAGR over the past five years.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $276.98M (+54.8% YoY); net profit $-59.50M.
- Trailing 12 Months Year-on-year growth — revenue +35.1%.
- 5-Year Trend Long-term compounding — revenue CAGR 14.3%, profit CAGR 23.4%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 14.34% |
| 1 Year: | 35.10% |
Compounded Profit Growth
| 5 Years: | 23.43% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +85.67% |
| 6 Months: | +36.07% |
| 3 Months: | +51.77% |
| 1 Month: | +14.50% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- Golden Cross9d ago
- RSI (14)62.25 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 14.3% over 5 years.
- Profit CAGR of 23.4% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ADPT Adaptive Biotechnologies Corporation R2K | 21.44 | -67.00 | $3.43B | 0.00% | -11.28% | -23.96% | 14.34% | 23.43% |
| 2 | LLY Eli Lilly and Company SPX | 1,152.54 | 41.02 | $1.03T | 0.61% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 253.85 | 29.45 | $611.07B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.78 | 119.40 | $432.48B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 425.19 | 32.02 | $386.13B | 2.27% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 120.78 | 34.02 | $298.31B | 2.86% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 164.50 | 24.81 | $255.12B | 1.77% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 534.07 | 29.33 | $198.47B | 0.40% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 355.25 | 24.69 | $191.73B | 2.84% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 11.57M | 17.19M | 12.67M | 22.14M | 26.06M | 20.91M | 20.99M | 26.30M | 38.44M | 38.51M | 39.47M | 38.62M | 43.66M | 47.83M | 37.65M | 48.93M | 37.92M | 41.87M | 43.19M | - | - | 52.44M | 58.88M | 93.97M | 71.68M | 70.87M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 16.98M | 18.00M | 18.16M | 18.22M | 18.71M |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 35.46M | 40.88M | 75.82M | 53.46M | 52.17M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 65.07M | 65.92M | 65.53M | 66.23M | 71.37M |
| Operating Income | -13.31M | -9.16M | -20.05M | -16.11M | -18.05M | -34.62M | -36.91M | -37.05M | -41.28M | -49.77M | -56.33M | -63.07M | -52.50M | -45.43M | -57.19M | -47.82M | -50.96M | -48.76M | -47.32M | - | - | -29.60M | -25.04M | 10.29M | -12.77M | -19.21M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -22.19M | -18.14M | 16.92M | -6.43M | -13.29M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.90M | 2.95M | 2.97M | 2.95M | 2.89M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -29.83M | -25.59M | 9.54M | -13.58M | -20.02M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -12.49M | -8.29M | -18.39M | -15.66M | -13.95M | -31.40M | -33.53M | -36.72M | -40.64M | -49.30M | -55.90M | -62.74M | -52.05M | -45.28M | -57.70M | -47.81M | -50.30M | -47.51M | -46.22M | - | - | -29.85M | -25.61M | 9.55M | -13.58M | -20.03M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | -0.35 | -0.40 | -0.44 | -0.37 | -0.32 | -0.40 | -0.33 | -0.35 | -0.33 | -0.31 | - | - | -0.20 | -0.17 | 0.06 | -0.09 | -0.13 |
| R&D Expense | 9.45M | 9.78M | 12.48M | 16.53M | 20.51M | 23.93M | 25.99M | 30.31M | 33.77M | 37.80M | 36.07M | 37.84M | 37.04M | 35.66M | 32.60M | 32.24M | 28.53M | 30.25M | 25.35M | 24.16M | - | 24.20M | 24.13M | 23.67M | - | 23.62M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 38.45M | 55.66M | 85.07M | 98.38M | 154.34M | 185.31M | 170.28M | 178.96M | 276.98M |
| Cost of Revenue | - | - | - | - | - | 57.91M | 75.55M | 72.08M | 71.36M |
| Gross Profit | - | - | - | - | - | 127.40M | 94.72M | 106.88M | 205.62M |
| Operating Expenses | - | - | - | - | - | 327.58M | 296.33M | 262.22M | 262.74M |
| Operating Income | -44.48M | -49.76M | -78.39M | -152.82M | -208.97M | -200.19M | -201.61M | -155.34M | -57.12M |
| EBITDA | - | - | - | - | - | -175.21M | -189.27M | -128.76M | -29.85M |
| Interest Expense | - | - | - | - | - | 4.24M | 13.80M | 11.58M | 11.78M |
| Pretax Income | - | - | - | - | - | -200.37M | -225.30M | -159.59M | -59.46M |
| Tax Provision | - | - | - | - | - | - | - | - | - |
| Net Income | -42.83M | -46.45M | -68.61M | -146.23M | -207.28M | -200.19M | -225.25M | -159.49M | -59.50M |
| Diluted EPS | - | - | - | -1.11 | -1.48 | -1.40 | -1.56 | -1.08 | -0.39 |
| R&D Expense | 32.00M | 39.16M | 70.70M | 116.07M | 142.34M | 141.76M | 122.12M | 102.95M | 93.77M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 332.69M | 912.30M | 1.12B | - | 856.62M | 661.13M | 539.38M | 512.74M |
| Current Assets | - | - | - | - | - | - | 562.15M | 410.19M | 283.75M | 300.19M |
| Cash & Equivalents | - | - | 55.03M | 96.58M | 123.44M | - | 90.03M | 65.06M | 47.92M | 70.50M |
| Inventory | - | - | - | - | - | - | 14.45M | 14.45M | 8.44M | 9.82M |
| Receivables | - | - | - | - | - | - | 40.06M | 37.97M | 41.73M | 50.37M |
| Total Liabilities | - | - | 29.94M | 341.26M | 373.15M | - | 392.52M | 352.86M | 336.89M | 287.74M |
| Current Liabilities | - | - | 22.80M | 78.31M | 105.20M | - | 109.79M | 88.02M | 98.05M | 89.92M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | - | - | 108.00M | 98.77M | 89.39M | 79.15M |
| Total Equity | -189.73M | -224.62M | -258.11M | 571.04M | 743.27M | - | 464.17M | 308.40M | 202.71M | 218.79M |
| Shares Outstanding | - | - | - | - | - | - | 143.11M | 145.08M | 147.77M | 153.78M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -34.86M | -32.26M | 205.40M | -149.68M | - | -183.94M | -156.32M | -95.21M | -45.99M |
| Investing Cash Flow | 36.43M | 736.00K | -481.70M | -117.04M | - | 2.90M | 129.65M | 77.79M | 37.95M |
| Financing Cash Flow | 50.03M | 1.25M | 319.92M | 293.59M | - | 132.26M | 2.25M | 241.00K | 30.40M |
| Capital Expenditure | -2.42M | -6.30M | -11.20M | -18.80M | - | -16.35M | -10.70M | -3.66M | -2.96M |
| Free Cash Flow | -37.28M | -38.56M | 194.20M | -168.49M | - | -200.29M | -167.02M | -98.88M | -48.95M |
| Net Change in Cash | - | - | - | - | - | -48.77M | -24.43M | -17.18M | 22.37M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | 68.7% | 55.6% | 59.7% | 74.2% |
| Operating Margin % | -115.7% | -89.4% | -92.1% | -155.3% | -135.4% | -108.0% | -118.4% | -86.8% | -20.6% |
| Net Margin % | -111.4% | -83.4% | -80.6% | -148.6% | -134.3% | -108.0% | -132.3% | -89.1% | -21.5% |
| ROE % | 19.1% | 18.0% | -12.0% | -19.7% | - | -43.1% | -73.0% | -78.7% | -27.2% |
| ROCE % | - | -16.1% | -9.4% | -15.1% | - | -26.8% | -35.2% | -35.2% | -13.5% |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ADPT
An Adaptive Biotechnologies Insider Sold $8.5 Million in Stock After an 85% Run
Harlan Robins liquidated 386,240 shares under a pre-scheduled Rule 10b5-1 trading plan, retaining over 1 million shares worth $21.6 million.
Adaptive Biotechnologies to Report Second Quarter 2026 Financial Results on July 29, 2026
SEATTLE, July 09, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose an…
Imviva Biotech Receives FDA IDE Authorization for clonoSEQ® Assay in TENACITY-01 Clinical Trial
Highly sensitive next-generation sequencing-based MRD testing will identify eligible patients with T-cell malignancies for trial enrollment and precisely evaluate treatment responseBOSTON, June 30, 2026 (GLOBE NEWSWIRE) -- Imviva Biotech, a…
Global Hematologic Malignancies Testing Market Size/Share Worth USD 12.47 Billion by 2035 at a 14.4% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, SWOT Analysis)
[220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global Hematologic Malignancies Testing Market size & share revenue was valued at approximately USD 3.28 Billion in 2…
BTIG Maintains a Buy Rating on Adaptive Biotechnologies (ADPT)
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) is one of the Best Growth Stocks to Buy and Hold for the Next Decade. On June 17, BTIG maintained a Buy rating on Adaptive Biotechnologies Corporation (NASDAQ:ADPT) with a $22 price target…
Adaptive Biotechnologies Corporation Prices Upsized $300 Million Convertible Senior Notes Offering
Proceeds expected to be deployed to repay the OrbiMed Purchase Agreement to enhance financial flexibilityAdditional proceeds used to pay for the capped call with a premium of 100% and to repurchase $25 million of common stock to reduce pote…
ADPT — Frequently Asked Questions
What is the current share price of Adaptive Biotechnologies Corporation (ADPT)?
As of 2026-07-14 21:23 PDT, Adaptive Biotechnologies Corporation (ADPT) trades at $21.44 on NasdaqGS. Its 52-week range is $10.24 to $22.37.
What is the market capitalisation of ADPT?
Adaptive Biotechnologies Corporation (ADPT) has a market capitalisation of $3.43B on NasdaqGS.
What is the P/E ratio of ADPT?
ADPT trades at a trailing price-to-earnings (P/E) ratio of -67.00. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 12.99.
What is the return on equity (ROE) of ADPT?
ADPT has a return on equity (ROE) of -23.96%. Its return on capital employed (ROCE) is -11.28%.
Is ADPT a good stock to buy?
This page provides a data-driven analysis of Adaptive Biotechnologies Corporation (ADPT), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.